Arecor Therapeutics PLC (AREC) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.178x

Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has a cash flow conversion efficiency ratio of -0.178x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.15 Million ≈ $-139.56 USD) by net assets (GBX6.45 Million ≈ $785.27 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Arecor Therapeutics PLC to measure how much of total assets are equity-financed.

Arecor Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Arecor Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AREC cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Arecor Therapeutics PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Arecor Therapeutics PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
SMG EUROPEAN RECOV. EO 1 F:RCVR	N/A
Global Gas Corporation NASDAQ:HGAS	0.137x
Sejahtera Bintang Abadi Textile Tbk JK:SBAT	-0.023x
M Winkworth PLC LSE:WINK	0.190x
PCI Biotech Holding ASA OL:PCIB	-0.501x
Jpmorgan Global Core Real Assets Ltd LSE:JARA	0.046x
Virpax Pharmaceuticals Inc NASDAQ:VRPX	3.142x
ImmuPharma PLC LSE:IMM	-2.979x

Annual Cash Flow Conversion Efficiency for Arecor Therapeutics PLC (2018–2025)

The table below shows the annual cash flow conversion efficiency of Arecor Therapeutics PLC from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Arecor Therapeutics PLC.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	GBX6.45 Million ≈ $785.27	GBX-2.29 Million ≈ $-278.63	-0.355x	+79.27%
2024-12-31	GBX5.35 Million ≈ $650.82	GBX-9.15 Million ≈ $-1.11K	-1.712x	-179.16%
2023-12-31	GBX9.53 Million ≈ $1.16K	GBX-5.84 Million ≈ $-710.68	-0.613x	+0.73%
2022-12-31	GBX17.45 Million ≈ $2.12K	GBX-10.78 Million ≈ $-1.31K	-0.618x	-110.20%
2021-12-31	GBX18.55 Million ≈ $2.26K	GBX-5.45 Million ≈ $-663.11	-0.294x	+87.75%
2020-12-31	GBX773.79K ≈ $94.15	GBX-1.86 Million ≈ $-225.90	-2.399x	-1577.65%
2019-12-31	GBX3.21 Million ≈ $390.31	GBX-458.80K ≈ $-55.82	-0.143x	+75.93%
2019-05-31	GBX4.22 Million ≈ $512.95	GBX-2.50 Million ≈ $-304.76	-0.594x	+19.14%
2018-05-31	GBX670.33K ≈ $81.56	GBX-492.57K ≈ $-59.93	-0.735x	--

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$275.63K

GBX2.27 Billion GBX

Market Cap Rank

#31116 Global

#992 in UK

Share Price

GBX60.00

Change (1 day)

-1.64%

52-Week Range

GBX59.00 - GBX92.50

All Time High

GBX450.00